Advancing precision in lung cancer diagnostics: Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC. (Courtesy of Lunit)
What You Should Know:
– Lunit, a provider of AI…
Continue Reading
AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.According to Owkin, BRCA…
Continue Reading
UK-based healthcare technology company Huma announced it secured more than $80 million in a Series D funding round, bringing its total raise to over $300 million. New and existing investors, including AstraZeneca, Leaps by Bayer,…
Continue Reading
What You Should Know:
– Mika Health, a leading developer of digital therapeutics for cancer patients, announced a collaborative initiative called “UNITE” alongside pharmaceutical giants AstraZeneca and Daiichi Sankyo.
– The strategic initiative signifies a commitment…
Continue Reading
Oncology-focused digital therapeutics company Mika Health announced a partnership with pharma companies AstraZeneca and Daiichi Sankyo for an initiative dubbed “UNITE” to provide digital therapeutics to women undergoing breast cancer treatments. Mika Health’s app gives…
Continue Reading
What You Should Know:
– Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
– The strategic investment bolsters…
Continue Reading
A research collaboration between Brainomix and AstraZeneca has shown that Brainomix’s AI-powered e-Lung software can more accurately identify lung fibrosis patients most at risk of decline.Brainomix published a study in the peer-reviewed journal ‘American…
Continue Reading
What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).The acquisition marks a major step forward in AstraZeneca delivering on its ambition to…
Continue Reading
What You Should Know:
– AstraZeneca has announced the acquisition of Icosavax, a biopharmaceutical company developing a promising vaccine targeting both RSV and hMPV, for a total of up to $1.1 billion.
– This acquisition strengthens…
Continue Reading
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help…
Continue Reading
